119 related articles for article (PubMed ID: 18310916)
1. Effect of acute hepatic failure on epirubicin pharmacokinetics after intrahepatic arterial injection in rats.
Nagata M; Matsuo Y; Hidaka M; Kawano Y; Okumura M; Tokunaga J; Takamura N; Arimori K
Biol Pharm Bull; 2008 Mar; 31(3):493-6. PubMed ID: 18310916
[TBL] [Abstract][Full Text] [Related]
2. Effect of acute hepatic failure on the hepatic first-pass effect of 5-fluorouracil in rats.
Nagata M; Hidaka Y; Hidaka M; Kawano Y; Iwakiri T; Okumura M; Arimori K
J Pharm Pharmacol; 2010 May; 62(5):598-603. PubMed ID: 20609061
[TBL] [Abstract][Full Text] [Related]
3. Potential advantages of loco-regional intra-arterial chemotherapy.
Cagol PP; Pasqual E; Bacchetti S
In Vivo; 2006; 20(6A):777-9. PubMed ID: 17203767
[TBL] [Abstract][Full Text] [Related]
4. Hepatic uptake of epirubicin by isolated rat hepatocytes and its biliary excretion after intravenous infusion in rats.
Shin DH; Park SH; Jeong SW; Park CW; Han K; Chung YB
Arch Pharm Res; 2014 Dec; 37(12):1599-606. PubMed ID: 25373308
[TBL] [Abstract][Full Text] [Related]
5. Hepatic fibrosis does not affect the pharmacokinetics of 5-fluorouracil in rats.
Nagata M; Hidaka Y; Hatakeyama K; Kawano Y; Iwakiri T; Okumura M; Arimori K
Biopharm Drug Dispos; 2011 Mar; 32(2):126-30. PubMed ID: 21341281
[TBL] [Abstract][Full Text] [Related]
6. Disposition of epirubicin after intraarterial administration in Lipiodol to patients with hepatocellular carcinoma.
Dodds HM; Walpole ET; Rivory LP; Strong RW; Pond SM
Ther Drug Monit; 1996 Oct; 18(5):537-43. PubMed ID: 8885116
[TBL] [Abstract][Full Text] [Related]
7. Antitumoral efficacy and pharmacokinetic properties of pirarubicin upon hepatic intra-arterial injection in the rabbit V x 2 tumour model.
Okada M; Kudo S; Miyazaki O; Saino T; Ekimoto H; Iguchi H; Hirano S; Kuboki H; Kadosawa H; Takeuchi T
Br J Cancer; 1995 Mar; 71(3):518-24. PubMed ID: 7880733
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of epirubicin emulsion and solution in rabbits after intrahepato-arterial and intravenous injection.
Lee K; Chan K
Methods Find Exp Clin Pharmacol; 1992 Oct; 14(8):655-9. PubMed ID: 1494305
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of gelatin sponge microparticles in a rabbit VX2 liver tumor model of hepatic arterial chemoembolization.
Zhang YW; Ao J; Liu Y; Qiao MX; Yang XL; Tang SX; Li C; Xu K
Tumour Biol; 2014 Nov; 35(11):10905-10. PubMed ID: 25085588
[TBL] [Abstract][Full Text] [Related]
10. Epirubicin in hepatocellular carcinoma: pharmacokinetics and clinical activity.
Dobbs NA; Twelves CJ; Rizzi P; Warwick JD; Metivier EM; Williams R; Johnson PJ
Cancer Chemother Pharmacol; 1994; 34(5):405-10. PubMed ID: 8070007
[TBL] [Abstract][Full Text] [Related]
11. Epirubicin and its metabolites levels in experimental liver metastases after different administration routes.
Bacchetti S; Pasqual E; Cagol PP
J Exp Clin Cancer Res; 2003 Dec; 22(4 Suppl):181-5. PubMed ID: 16767928
[TBL] [Abstract][Full Text] [Related]
12. Factors affecting epirubicin pharmacokinetics and toxicity: evidence against using body-surface area for dose calculation.
Gurney HP; Ackland S; Gebski V; Farrell G
J Clin Oncol; 1998 Jul; 16(7):2299-304. PubMed ID: 9667243
[TBL] [Abstract][Full Text] [Related]
13. An exploratory study of body composition as a determinant of epirubicin pharmacokinetics and toxicity.
Prado CM; Lima IS; Baracos VE; Bies RR; McCargar LJ; Reiman T; Mackey JR; Kuzma M; Damaraju VL; Sawyer MB
Cancer Chemother Pharmacol; 2011 Jan; 67(1):93-101. PubMed ID: 20204364
[TBL] [Abstract][Full Text] [Related]
14. Disposition of epirubicin in an oily contrast medium after intravenous and intrahepato-arterial administration in liver cancer: a preliminary report.
Lee K; Chan K; Leung WT; Leung NW; Ho S; Chan M; Lau CC; Tao M; Lau WY; Shiu W
Eur J Drug Metab Pharmacokinet; 1992; 17(3):221-6. PubMed ID: 1337040
[TBL] [Abstract][Full Text] [Related]
15. Lattice intrahepatic doxorubicin with and without in-flow occlusion: a pharmacokinetic study of direct liver injection.
Averbach A; Stuart OA; Chang D; Sugarbaker PH
Eur J Surg Oncol; 2000 Feb; 26(1):73-9. PubMed ID: 10718184
[TBL] [Abstract][Full Text] [Related]
16. Augmentation of hepatic doxorubicin extraction with extracorporeal filtration avoids the dose-dependent, nonlinear increase in AUC observed with systemic administration.
Sturgill MG; Brenner DE; August DA
Cancer Chemother Pharmacol; 1998; 41(3):193-200. PubMed ID: 9443635
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of epirubicin-induced acute oxidative stress toxicity in rat liver cells and mitochondria, and the prevention of toxicity through quercetin administration.
Kebieche M; Lakroun Z; Lahouel M; Bouayed J; Meraihi Z; Soulimani R
Exp Toxicol Pathol; 2009 Mar; 61(2):161-7. PubMed ID: 18657957
[TBL] [Abstract][Full Text] [Related]
18. Effect of low-protein diet on anthracycline pharmacokinetics and cardiotoxicity.
El-Demerdash E; Ali AA; El-Taher DE; Hamada FM
J Pharm Pharmacol; 2012 Mar; 64(3):344-52. PubMed ID: 22309266
[TBL] [Abstract][Full Text] [Related]
19. [Effect on hepatic function of hepatic artery infusion chemotherapy using epirubicin and mitoxantrone for advanced hepatocellular carcinoma].
Murata T; Nasu R; Kimura H; Uokawa K; Nagata K; Akagi K; Tanaka Y
Gan To Kagaku Ryoho; 1998 Sep; 25(11):1707-11. PubMed ID: 9757196
[TBL] [Abstract][Full Text] [Related]
20. The effect of cimetidine on the pharmacokinetics of epirubicin in patients with advanced breast cancer: preliminary evidence of a potentially common drug interaction.
Murray LS; Jodrell DI; Morrison JG; Cook A; Kerr DJ; Whiting B; Kaye SB; Cassidy J
Clin Oncol (R Coll Radiol); 1998; 10(1):35-8. PubMed ID: 9543613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
